Should triple inhaled therapy be initiated earlier in the disease course of COPD to modify long-term outcomes, including mortality, exacerbations, and cardiovascular risk?

BACKGROUND

Chronic obstructive pulmonary disease (COPD) is a progressive and heterogeneous disorder in which exacerbations accelerate lung-function decline, increase cardiovascular morbidity, and worsen mortality. Although single-inhaler triple therapy (SITT; ICS/LABA/LAMA) is currently recommended for patients with persistent symptoms or frequent exacerbations despite dual bronchodilation, emerging evidence suggests that earlier initiation may improve long-term outcomes.

OBJECTIVE

To evaluate whether earlier initiation of triple inhaled therapy in COPD could improve long-term outcomes, including lung-function preservation, exacerbation burden, mortality, cardiovascular risk, and healthcare resource utilisation.

EVIDENCE SYNTHESIS: Pivotal randomized trials such as IMPACT and ETHOS showed that SITT reduces exacerbations and improves lung function, with significant reductions in all-cause mortality and cardiopulmonary events in high-risk populations. Post hoc analyses and real-world studies suggest that symptomatic patients without frequent exacerbations may also benefit from earlier escalation. Predictive models, including DEPICT, ACCEPT, and GALAXY, consistently indicate that earlier initiation of SITT, particularly in younger or pre-exacerbator phenotypes, may preserve lung function, delay disease progression, reduce exacerbations, lower mortality risk, and remain cost-effective. These benefits appear to be mediated partly through exacerbation prevention and attenuation of post-exacerbation cardiovascular vulnerability.

CONCLUSIONS

Converging evidence from clinical trials, real-world studies, and predictive modelling supports the hypothesis that earlier initiation of SITT may represent a disease-modifying strategy in selected patients with COPD. Prospective pragmatic trials are needed to define optimal timing, target populations, and the balance between benefit and risk.